Overall, joint involvement and thrombocytopenia from a clinical point of view, positivity for anti-dsDNA/anti-Sm antibodies and low C3/C4 serum levels from a serological point of view, were significantly more frequent in reclassified patients at first or last evaluation. This evidence concerns the gene C3 and Thrombocytopenia.